Given the dual role of mTOR inhibitors in suppressing posttransplantation rejection and reducing the risk of posttransplantation tumorigenesis, they are essential for the prevention and treatment of specific types of posttransplantation cancers. The gene discussed is MTOR; the disease is cancer.